This site is intended for health professionals only

Sunday 20 October 2019
Share |

New heart failure medicine LCZ696 to be available to the NHS under the Early Access to Medicines Scheme

Novartis announced that its investigational heart failure treatment LCZ696 (sacubitril valsartan) has been given a positive scientific opinion under the Medicines and Healthcare products Regulatory Agency (MHRA) Early Access to Medicines Scheme (EAMS) for patients with significant unmet medical need.  This allows LCZ696 (sacubitril valsartan) to be made available to eligible patients before a final European licensing decision is made.
 
It is the first time a drug not intended to treat cancer has been recognised under EAMS.